SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

May 31, 2024

Accounting Policies [Abstract]

SCHEDULE OF NET INVENTORIES

The following is a summary of approximate net inventories:

	May 31,
	2024			2023
Raw materials	$	1,519,000		$	1,677,000
Work in progress		1,145,000			869,000
Finished products		179,000			182,000
Total gross inventory	$	2,843,000		$	2,728,000
Inventory reserve		(467,000	)		(672,000	)
Net inventory	$	2,376,000		$	2,056,000

SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS

In applying the Black-Scholes option-pricing model, the following assumptions used in the valuation of awards issued for years ended May 31, 2024 and 2023:

	For the year ended May 31,
	2024			2023
Dividend yield		0	%		0	%
Expected volatility		100.54 - 111.98	%		98.81 - 101.77	%
Risk free interest rate		4.0 - 4.59	%		3.12 - 3.35	%
Expected term		4.69 - 6.25 years			6.25 years

SCHEDULE OF DISAGGREGATION REVENUE

The following is an approximate breakdown of revenues according to primary markets to which the products are sold:

	For Year Ended May 31,
	2024		2023
Clinical lab	$	3,236,000	$	3,310,000
Over-the-counter		1,426,000		1,169,000
Contract manufacturing		741,000		610,000
Physician’s office		12,000		250,000
Total	$	5,415,000	$	5,339,000